Clinical Study Grants
Supports large, late-phase clinical trials and major observational studies to drive impactful, practice-changing research in cardiovascular medicine.
Funder: British Heart Foundation
Due Dates: January 14, 2026 (Full application, April 2026 Committee) | April 23, 2026 (Preliminary, May 2026 panel) | July 1, 2026 (Full application, October 2026 Committee) | August 27, 2026 (Preliminary, September 2026 panel) | October 22, 2026 (Preliminary, November 2026 panel)
Funding Amounts: No formal cap; awards typically exceed £500,000 or last over 4 years.
Summary: Supports large, late-phase clinical trials and major observational studies in cardiovascular medicine to drive impactful changes in patient care.
Key Information: Two-stage application: preliminary then full; UK-based PI required; value for money and impact are critical.
Description
This scheme funds ambitious, practice-changing clinical research in cardiovascular medicine. Grants support large-scale, late-phase (phase III/IV) interventional trials and major hypothesis-driven observational studies involving specific patient groups. Projects must aim to deliver significant impact on patient care—nationally or internationally—and typically require budgets over £500,000 or durations exceeding four years. Mechanistic sub-studies can be included. The program is designed for studies that address well-defined clinical questions with measurable outcomes, but does not support open-ended epidemiological or omics-focused cohort studies.
BHF encourages collaborations, including international studies led by UK-based researchers, and expects applications to demonstrate scientific excellence, feasibility, and clear potential for clinical impact. Applicants are encouraged to work with the BHF Clinical Research Collaborative to ensure their study addresses priority questions in the field.
